Editor's note

This ExpertREACT article was originally published on 10 June 2011 to coincide with the ASCO 2011 annual meeting. Pipeline statuses and clinical data described reflect the state of knowledge at that date.

A transformed treatment landscape

Each year approximately 200,000 cases of invasive melanoma are diagnosed worldwide, with 75% in developed Western countries affecting mostly people aged 60 years or older. Until 2011, effective options for patients with unresectable Stage III or Stage IV melanoma were virtually non-existent, with most patients enrolled in clinical trials for adjuvant agents. In March 2011, the US FDA approved Bristol-Myers Squibb's ipilimumab ('Yervoy'), a CTLA-4 monoclonal antibody designed to stimulate T-cell mediated anti-tumour immune responses. In Phase III trials, Yervoy demonstrated a statistically significant survival benefit of approximately four months in patients with unresectable or metastatic melanoma, albeit with high rates of severe immune-related side effects.

Roche's vemurafenib (a BRAF inhibitor) generated equally dramatic data around the same time, demonstrating rapid tumour regression in patients with BRAF V600E mutation-positive melanoma. Together, ipilimumab and vemurafenib fundamentally altered the treatment paradigm and raised the question of how therapeutic vaccines would be positioned relative to these new immuno-oncology agents. VacZine Analytics noted that ipilimumab had also been tested in combination with the investigational peptide melanoma vaccine gp100, with the combination showing less benefit than ipilimumab alone - an early signal that the competitive landscape for vaccine-based approaches was becoming more complex.

Ipilimumab survival benefit
~4 months
Statistically significant improvement in overall survival vs chemotherapy in previously treated unresectable/metastatic melanoma

MAGE-A3 and the therapeutic vaccine pipeline

GSK's MAGE-A3 ASCI programme remained the most advanced therapeutic melanoma vaccine in development, with Phase III trials ongoing for both melanoma and non-small cell lung cancer (NSCLC). VacZine Analytics' analysis, released to coincide with the 46th ASCO annual meeting in Chicago (3-7 June 2011), examined the commercial potential of melanoma vaccines in the evolving post-ipilimumab landscape. The conclusion was nuanced: the new immuno-oncology approvals raised the bar for therapeutic vaccines but also validated the broader concept of immunological approaches to melanoma - potentially strengthening the longer-term case for combination strategies incorporating therapeutic vaccines.